PharmaMar Announces New Data with its Compounds Yondelis® and Lurbinectedin During ASCO 2017
Pubblicato il: 19/05/2017 09:01
MADRID, May 19, 2017 /PRNewswire/ --
PharmaMar (MCE: PHM) will present data obtained from various clinical studies for its activated transcription inhibitors, Yondelis
®and lurbinectedin, during the 53
rdCongress of the American Society of Clinical Oncology (ASCO) that will be held from the 2
ndto the 6
thof June in Chicago (USA).
During this congress, PharmaMar will participate with various presentations for Yondelis® in malignant pleural mesothelioma, along with the data of a prospective study of the combination with radiotherapy in soft tissue sarcoma.
The Company will also present data for lurbinectedin (PM1183) for the treatment of endometrial cancer and BRCA 2-associated metastatic breast cancer. The results will also be presented on a Phase I study that evaluated the combination of lurbinectedin with olaparib in patients with advanced solid tumors.
"After the positive results obtained in endometrial cancer with lurbinectedin, as a single agent and in combination with doxorubicin (abstract 6658), weplan to initiate a pivotal Phase III study.We have reached anagreement with the US FDA on the designof the study", explains Dr Arturo Soto, Head of Clinical Development at the Oncology Business Unit at PharmaMar. "We will continue withour commitment to finding innovative solutions for cancer patients from compounds of a marine origin that have the characteristic for combating cancer with a novel mechanism of action", states.
The studies presented during this congress are available on
Principle studies to be presented at ASCO 2017
Poster Board: #408. Saturday 3 of June from 13:15 to 16:45. Hall A
Lead author: Martin David Forster, MBBS, MRCP, FRCP, PhD, University College London Hospitals
Poster Board: #174. Sunday, 4 of June from 8:30 to 11:30. Hall A
Lead author: Judith Balmana Gelpi, MD PhD, Hospital Vall d'Hebron
Poster Board: #395. Saturday, 3 of June from 13:15 to 16:45. Hall A
Lead autjor: Andres Poveda, MD, Clinical Area of Gynecologic Oncology, Instituto Valenciano de Oncología (IVO)
Poster Board: #249. Saturday, 3 of June from 13:15 to 14:30. Hall D2
Laed author: Diego Luigi Cortinovis, MD, Azienda Ospedaliera San Gerardo
Poster Board: #383. Sunday, 4 of June from 8:00 to 11:30. Hall A
Lead author: Sivan Shamai, MD, Tel Aviv Medical Center and Sackler School of Medicine
Poster Board: #384. Sunday, 4 of June from 8:00 to 11:30. Hall A
Laed author: Alessandro Gronchi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori
Poster Board: #393. Sunday, 4 of June from 8:00 to 11:30. Hall A
Laed author: Javier Martinez-Trufero, PhD, Hospital Miguel Servet
Poster Board: #394. Sunday, 4 of June from 8:00 to 11:30. Hall A
Laed author: Javier Martin Broto, MD, PhD, Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)
Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)